Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Nevro Corp (NVRO)

Nevro Corp (NVRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,309,972
  • Shares Outstanding, K 31,007
  • Annual Sales, $ 387,290 K
  • Annual Income, $ -49,210 K
  • 60-Month Beta 0.46
  • Price/Sales 10.52
  • Price/Cash Flow N/A
  • Price/Book 20.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -1.02
  • Number of Estimates 6
  • High Estimate -0.85
  • Low Estimate -1.16
  • Prior Year -1.45
  • Growth Rate Est. (year over year) +29.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
130.48 +3.92%
on 02/25/20
148.05 -8.42%
on 02/26/20
+2.09 (+1.57%)
since 01/27/20
3-Month
107.11 +26.58%
on 12/12/19
148.05 -8.42%
on 02/26/20
+22.95 (+20.37%)
since 11/27/19
52-Week
42.82 +216.65%
on 03/15/19
148.05 -8.42%
on 02/26/20
+90.19 (+198.66%)
since 02/27/19

Most Recent Stories

More News
Nevro (NVRO) Q4 Loss Narrower Than Expected, Revenues Up Y/Y

Nevro (NVRO) sees strong segmental contributions in Q4.

SYK : 194.85 (-3.38%)
ARAY : 2.97 (-3.26%)
IDXX : 250.15 (-3.58%)
NVRO : 135.59 (-2.45%)
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates

Nevro (NVRO) delivered earnings and revenue surprises of 29.03% and 3.20%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

NVRO : 135.59 (-2.45%)
Nevro: 4Q Earnings Snapshot

REDWOOD CITY, Calif. (AP) _ Nevro Corp. (NVRO) on Tuesday reported a loss of $13.7 million in its fourth quarter.

NVRO : 135.59 (-2.45%)
What in Store for Universal Health's (UHS) Q4 Earnings?

Universal Health's (UHS) Q4 results are likely to reflect gains from both its Acute Care and Behavioral Health segments.

UHS : 128.24 (-5.15%)
AMAG : 7.54 (-5.51%)
ADRO : 2.97 (-13.16%)
NVRO : 135.59 (-2.45%)
What's in Store for Patterson Companies' (PDCO) Q3 Earnings?

Patterson Companies (PDCO) expects Animal Health sales to have been soft in fiscal Q3.

ABM : 35.31 (-1.48%)
PDCO : 24.01 (+5.86%)
BURL : 221.24 (-5.44%)
NVRO : 135.59 (-2.45%)
Why Earnings Season Could Be Great for Nevro (NVRO)

Nevro (NVRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

NVRO : 135.59 (-2.45%)
What's in Store for Fulgent Genetics (FLGT) Q4 Earnings?

Fulgent Genetics' (FLGT) fourth-quarter 2019 earnings are likely to reflect top-line growth and elevated test volumes.

BAX : 84.27 (-3.17%)
HQY : 73.94 (-2.32%)
NVRO : 135.59 (-2.45%)
FLGT : 15.92 (-7.01%)
What's in Store for Tenet Healthcare's (THC) Q4 Earnings?

Tenet Healthcare's (THC) Q4 results are likely to reflect higher revenues, aided by its Hospital and Other Operations as well as Ambulatory segments, partly offset by lower admissions.

THC : 26.74 (-3.81%)
ADPT : 28.32 (-4.49%)
ADRO : 2.97 (-13.16%)
NVRO : 135.59 (-2.45%)
What's in the Cards for EverQuote's (EVER) Q4 Earnings?

EverQuote's (EVER) Q4 results are likely to reflect revenue growth and expansion in EBITDA.

MGA : 45.52 (-2.82%)
EVER : 38.24 (-2.37%)
NVRO : 135.59 (-2.45%)
WW : 31.45 (+0.61%)
MEDNAX (MD) Q4 Earnings and Revenues Surpass Estimates

Mednax's (MD) Q4 results reflect growth in same unit revenues and lower general and administrative expenses.

MD : 17.02 (-1.56%)
ADPT : 28.32 (-4.49%)
ADRO : 2.97 (-13.16%)
NVRO : 135.59 (-2.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade NVRO with:

Business Summary

Nevro Corp. is a medical device company. It engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. Nevro has developed and commercialized the Senza...

See More

Key Turning Points

2nd Resistance Point 143.10
1st Resistance Point 139.35
Last Price 135.59
1st Support Level 132.74
2nd Support Level 129.88

See More

52-Week High 148.05
Last Price 135.59
Fibonacci 61.8% 107.85
Fibonacci 50% 95.43
Fibonacci 38.2% 83.02
52-Week Low 42.82

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar